Vaishali Pharma IPO (DHRP IPO Review Share Price Date)

Vaishali Pharma IPO : Below is the Review of Vaishali Pharma (Also Vaishali PharmaShare Price, IPO Date, DRHP etc). Vaishali Pharma is still in the beginning stages and the company has filed a Draft Red Herring Prospectus with the SEBI. Vaishali Pharma looks to raise around Rs.2,800 Crore ($44 million dollars) through this IPO. The IPO from Vaishali Pharma is one of the many companies going for a Public Issue in the coming months, along with Prataap Snacks and also Majestic Research IPO. Below, the Draft Prospectus of Vaishali Pharma is available for Download in PDF Format.

Vaishali Pharma IPO Details

Issue Capital Rs.2,800 Crore
DHRP Download
IPO Date Late This Year
Shares for Sale 19,76,000

Revenues : Vaishali Pharma IPO

The Revenue from Operations of Vaishali Pharma Ltd for the year ending March 31, 2017 is Rs. 6,605.48 lakhs as compared to Rs. 6,670.72 lakhs for the year ending March 31, 2016, showing a decrease of 0.98%. The decrease was mainly due to decrease in our domestic business operations.

Other Income

Vaishali Pharma Ltd other income decreased by 66.79% to Rs. 105.74 lakhs in FY 2016-17 from Rs. 318.40 lakhs in FY 2015-16. The decrease was mainly due to decrease in interest income on delayed payment form customers.

Employee Expenses : Vaishali Pharma IPO

Vaishali Pharma Ltd Employee benefit expenses increased from Rs. 155.69 lakhs in financial year 2015-16 to Rs. 157.63 Lakhs in financial year 2016-17 due to increase in our contribution to provident & superannuation fund.

Vaishali Pharma Ltd other expenses increased by 45.19% from Rs. 256.97 lakhs in financial year 2015-16 to Rs. 373.10 lakhs in financial year 2016-17. The increase was mainly due to increase in transport expenses on account of increase in export operations.

Also during FY 2016-17 there has been significant rise in Vaishali Pharma Ltd legal & professional charges due to increase in Consultancy Charges for getting Assistance in Registration of brands in Foreign Countries and Export Orders.

Authorization for the Vaishali Pharma IPO

The Board of Directors of Vaishali Pharma Ltd have, pursuant to Section 62(1)(c) of the Companies Act 2013, by a resolution passed at its meeting held on June 21, 2017, authorized the Issue, subject to the approval of the shareholders and such other authorities as may be necessary.

The shareholders of Vaishali Pharma Ltd have, pursuant to Section 62(1)(c) of the Companies Act 2013, by a special resolution passed in the Extra-Ordinary General Meeting/Annual General Meeting held on June 21, 2017 authorized the Issue.

Industry Conditions : Vaishali Pharma IPO

Indian pharmaceutical sector accounts for about 2.4 per cent of the global pharmaceutical industry in value terms & 10 per cent in volume terms. India accounts for 20 per cent of global exports in generics.

In FY16, India exported pharmaceutical products worth USD16.89 billion, with the number expected to reach USD40 billion by 2020. Pharma exports in India grew at 9.44 per cent in FY16, registering an amount of US$16.9 billion.

The exports are expected to register double digit growth in FY17, with exports growing at 8 per cent in January 2017. The country‘s pharmaceutical industry is expected to expand at a CAGR of 12.89 per cent over 2015–20 to reach USD55 billion.

Indian healthcare sector, one of the fastest growing sectors, is expected to advance at a CAGR of 17 per cent to reach USD250 billion over 2008–20. The generics market stood at USD26.1 billion in 2016 from USD21 billion in 2015. India‘s generics market has immense potential for growth.

About the Company : Vaishali Pharma IPO

Founded in the year 1989, Vaishali Pharma Ltd., has achieved the Export House status through unwavering dedication, consistent efforts and endless innovation.

Legitimacy of Vaishali Pharma Ltd product’s quality has been certified by ISO 9001:2008 certification for the Quality Management from BM Trada UKAS and Credit Rating Certification from NSIC CRISIL.

Dedicated to developing Pharmaceutical Formulations, API’s, Surgicals, Veterinary, Herbal & Nutraceutical Products; Vaishali Pharma Ltd aim to deliver unique value to patients and societies all around the world.

Adapting quickly to the ever-evolving demands, Vaishali Pharma Ltd have emerged as one of the fastest growing organization in the pharmaceutical industry across the globe.

With Vaishali Pharma Ltd headquarters located amidst the economic hub of India, Mumbai, we have established our offices in Kenya, Turkey & Vietnam. Further widening Vaishali Pharma Ltd reach overseas, we have made a joint venture with D.R. Congo based company.

Vaishali Pharma Ltd. believe, “Quality is an ongoing process of building and sustaining relationships”. Vaishali Pharma Ltd strong commitment of providing quality products is boasted by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resultantly, creating mutually beneficial associations for all the parties involved.

Vaishali Pharma Ltd 70 + formulation brands are being marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. Our synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with our clients.

With a clear vision to spread our wings across the globe, and under the Leadership of Mr. Atul Vasani, Vaishali Pharma Ltd currently export Formulations, Surgical & APIs to Kenya, Sri Lanka, Russia, DR Congo, Myanmar, Tajikistan, Bangladesh, Kazakhstan, Cameroon, Jordan, Burkina -Faso, Nicaragua, Senegal, Pakistan, Ukraine, Yemen, Cambodia, Turkey, Congo, Zimbabwe, Ethiopia, Tanzania, Vietnam, Armenia, Costa Rica, Nigeria, C.A.R. and Guinea-Bissau.

Adhering to high quality standards is not an accident but Vaishali Pharma Ltd habit. Passionate to be the best, Vaishali Pharma Ltd take pride in what we do and strive to deliver products with 0% defects. One can count upon us for quality pharmaceutical and healthcare products.

Conclusion : Vaishali Pharma IPO

If you have any further questions on Vaishali Pharma IPO editorial, post your question on our comments section below. This article relating to Vaishali Pharma IPO was compiled by FinApp Editorial Team.